Lampalizumab |
| Katalog-Nr.GC72354 |
Lampalizumab (RG 7417) ist ein humanisierter monoklonaler Antikörper, der Komplementfaktor D im alternativen Komplementpfad zielt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1278466-20-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lampalizumab delivered intravenously to cynomolgus monkeys elicits nearly 10-fold increases in serum Factor D levels within five hours, effectively neutralizing its inhibitory activity[1].
References:
[1]. Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102(3):466-475.
[2]. Hanus J, et al. Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol. 2016 Jan;100(1):122-7.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *